Goldman Sachs raises Price Target on Edwards Lifesciences
Thursday, January 19, 2022 9:51 AM

Goldman Sachs has raised its price target on Edwards Lifesciences (EW) shares to $90 from $88 based on higher EPS estimates of $1.84 from $1.82. The brokerage also reiterated its Conviction List Buy on Edwards shares.

Analyst Donald Roman continues to view the company as one of the most compelling new product stories across all devices. He views the study conclusion as positive and raised his outer-year US PARTNER A estimates due to higher TAVI penetration in the surgery eligible patient group.

The analyst views come after the Society of Thoracic Surgeons (STS) released an abstract summarizing the conclusion from Edwards’ PARTNER A (PA) continued access protocol (CAP) study on transapical patients. The study came to conclusion that improvements were witnessed in the CAP group compared to PA in terms of major outcome variables death, stroke, and bleeding.

The brokerage lists key risks of share loss in valves, pressure on EU budgets and slower US product romp.